NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
63459-0910-15 | 63459-0910 | tbo-filgrastim | Granix | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 11, 2013 | In Use | |
63459-0912-12 | 63459-0912 | tbo-filgrastim | Granix | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 11, 2013 | In Use | |
61314-0312-01 | 61314-0312 | filgrastim-sndz | Zarxio | 480.0 ug/.8mL, 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Sep 3, 2015 | Feb 28, 2021 | No Longer Used |
70114-0120-01 | 70114-0120 | Pegfilgrastim-cbqv | UDENYCA | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Mar 6, 2023 | In Use | |
61314-0304-10 | 61314-0304 | filgrastim-sndz | Zarxio | 300.0 ug/.5mL, 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Sep 3, 2015 | Feb 28, 2021 | No Longer Used |
70114-0101-01 | 70114-0101 | pegfilgrastim-cbqv | UDENYCA | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 2, 2018 | In Use | |
54868-3050-00 | 54868-3050 | Filgrastim | Neupogen | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous | Aug 14, 2006 | In Use | |
63459-0912-11 | 63459-0912 | tbo-filgrastim | Granix | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 11, 2013 | In Use | |
63459-0910-11 | 63459-0910 | tbo-filgrastim | Granix | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 11, 2013 | In Use | |
70121-1571-07 | 70121-1571 | Filgrastim | RELEUKO | 480.0 ug/1.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Feb 25, 2022 | In Use | |
00078-0652-06 | 00078-0652 | Panobinostat | Farydak | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | HDAC | Oral | Feb 23, 2015 | Dec 31, 2022 | No Longer Used |
68152-0108-09 | 68152-0108 | Belinostat | Beleodaq | 500.0 mg/10mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Jul 21, 2014 | Nov 30, 2022 | In Use |
59572-0984-01 | 59572-0984 | Romidepsin | Istodax | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Jan 4, 2010 | In Use | ||
00078-0651-06 | 00078-0651 | Panobinostat | Farydak | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | HDAC | Oral | Feb 23, 2015 | Dec 31, 2022 | No Longer Used |
00703-3125-08 | 00703-3125 | Romidepsin | Romidepsin | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Aug 1, 2018 | Oct 31, 2021 | No Longer Used | |
00703-3071-01 | 00703-3071 | Romidepsin | Romidepsin | 5.0 mg/mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Apr 14, 2020 | In Use | |
00703-4004-01 | 00703-4004 | Romidepsin | Romidepsin | 5.0 mg/mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Apr 14, 2020 | In Use | |
00078-0650-06 | 00078-0650 | Panobinostat | Farydak | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | HDAC | Oral | Feb 23, 2015 | Jan 31, 2023 | No Longer Used |
63323-0926-88 | 63323-0926 | Romidepsin | Romidepsin | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Oct 12, 2021 | In Use | ||
46026-0983-01 | 46026-0983 | Romidepsin | Istodax | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Nov 5, 2009 | May 28, 2010 | No Longer Used | |
59572-0983-01 | 59572-0983 | Romidepsin | Istodax | Chemotherapy | Enzyme Inhibitor | HDAC | Jan 4, 2010 | In Use | |||
00006-0568-40 | 00006-0568 | Vorinostat | Zolinza | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | HDAC | Oral | Oct 6, 2006 | In Use | |
50242-0333-01 | 50242-0333 | Trastuzumab | Herceptin | Immunotherapy | Monoclonal Antibody | HER2 | Feb 10, 2017 | Feb 10, 2017 | No Longer Used | ||
50242-0260-86 | 50242-0260 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | May 3, 2021 | In Use | |
50242-0132-01 | 50242-0132 | Trastuzumab | Herceptin | 150.0 mg/7.4mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Feb 10, 2017 | In Use |
Found 11120 results — Export these results